Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| The Quality Unit for General Practice North Denmark Region | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Brief summary: The randomised controlled trial investigates the effect of a pharmacist intervention targeting polypharmacy patient at two levels medical clinics and patient level. The purpose is to gain more knowledge to patients and physicians about their medication and to see changes in the patient's medication and health-related quality of life.
The main objective of the randomised controlled trial is to investigate the clinical effects of the roll-out of the systematic offer from Nord-KAP in the North Denmark Region at two different levels (medical clinic and patient-level). The primary outcome is changes in the participant's medicine from baseline to follow up and changes in healthcare usage Secondary outcomes include investigation of cost-effectiveness and changes in patients health-related quality of life.
The hypothesis is that the regional intervention delivered by the pharmacists, from Nord-KAP, can lead to a decrease in medical products compared with a control group between baseline and at 6-month follow-up.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention group - Medical clinics | Experimental | Medical clinics receiving the pharmacist intervention described in the intervention group for patient level |
|
| Control group - medical clinics | No Intervention | All medical clinics that are enrolled in the trial will eventually receive the intervention at some point. As some medical clinics act as the control group to being with. | |
| Intervention group - patient level | Experimental | The intervention consists of two subgroups: Intervention pharmacist and intervention proposals. As the pharmacist conducts medication reviews of the polypharmacy patients in the medical clinic they can make a note to the physician about fx a specific medication the physician needs to pay attention to. These polypharmacy patients are enrolled in the group intervention proposals and are asked to complete questionaries at baseline and follow-up. Ultimately, it is up to the physician to react to the note in the polypharmacy patients medical record. Therefore the pharmacist only makes a note in the journal of the patient and does nothing else. The group intervention pharmacist is polypharmacy patients where the pharmacist conducts a medication review and develops suggested interventions proposals for each participant |
|
| Control group - patient level | No Intervention | The control group will have access to usual care and other health services within the healthcare systems. Participants randomised to the control group are invited to participate in the evaluation of the current treatment in the primary health care sector |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Systematic pharmacist intervention | Other | Already described in the arm group intervention group for patient level |
|
| Measure | Description | Time Frame |
|---|---|---|
| Changes in polypharmacypatients medication | The primary outcome at patient level is changes in the patients medication use at baseline and 6-month follow-up defined as the amount of medicine prescribed. Measuring the amount of medicine is extracted by the pharmacist from the participants SMC. | 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Health-related quality of life | HRQoL as measures of effect for the economic evaluations. HRQoL is measured by the EQ-5D-5L questionnaire and converted into quality of life which is a scale from o to 1 where 0 correspondts to death and 1 indicates perfect health | 6 months |
| Healthcare services |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jesper Søndergaard, MsC | Contact | +4599403527 | jhsxn@dcm.aau.dk |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The quality unit for genreal practice | Recruiting | Aalborg | North Denmark | Denmark |
Not provided
| Label | URL |
|---|---|
| Link to the homepage of the pharmacist intervention from the quality unit for general practice north denmark region | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
RCT of The intervention and control groups will both have access to their physician as usual. At the medical clinic level the intervention group will receive the pharmacist intervention and other medical clinics will act as control groups. At patient level the intervention group will receive the pharmacist intervention and the control group are asked to evaluate the current treatment option.
Not provided
Not provided
The medical clinics and polypharmacy patients are blinded from the randomisation process.
Use of healthcare services to estimate costs for the economic evaluation. Use of health care services are measured by Danish health registers. |
| 6 months months and long term follow-up |
| Healthcare services | Use of healthcare services to estimate costs for the economic evaluation. Use of health care services are measured by Danish health registers. | Up to 10 years |
| Amount of medicine pr patient in each medical clinic | The primary outcome for the medical clinics are changes in the patients medication at baseline and at six months follow-up | 6 months |
| Medical clinic number of polypharmacy patients | . A count of the total number of polypharmacy patients in each medical clinic is conducted at baseline and six months follow-up | 6 months |